Previous research has revealed the function of ARID1A mutation in impairing mismatch repair (MMR) function, increasing the tumor mutation burden (TMB) and predicting good prognosis to cancer immunotherapy in vivo [20]. The gene discussed is ARID1A; the disease is neoplasm.